AstraZeneca PLC Files Director Shareholding Report
Ticker: AZN · Form: 6-K · Filed: Nov 10, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Nov 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.25 |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-filing, regulatory-update, shareholding
Related Tickers: AZN
TL;DR
AZN filed its 6-K for director shareholdings - routine update.
AI Summary
AstraZeneca PLC filed a Form 6-K on November 10, 2025, reporting its shareholdings for Directors and Persons Disclosing Managerial Responsibilities (PDMRs). This filing is a routine report for foreign issuers and does not contain specific financial transaction details within the provided text.
Why It Matters
This filing provides transparency into the holdings of key company personnel, which can be an indicator of insider confidence in the company's future performance.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not contain information that suggests a change in the company's risk profile.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report
- 001-11960 (company) — SEC File Number for AstraZeneca PLC
- 20251110 (date) — Filing date and period of report
FAQ
What type of report is AstraZeneca PLC filing?
AstraZeneca PLC is filing a Form 6-K, which is a Report of Foreign Issuer.
When was this Form 6-K filed?
The Form 6-K was filed on November 10, 2025.
What is the SEC File Number for AstraZeneca PLC?
The SEC File Number for AstraZeneca PLC is 001-11960.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a report concerning Director/PDMR Shareholding.
Where is AstraZeneca PLC's principal executive office located?
AstraZeneca PLC's principal executive office is located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 19.6 · Accepted 2025-11-10 12:15:17
Key Financial Figures
- $0.25 — nterested in 136,537 ordinary shares of $0.25 each in the Company, following the gift
Filing Documents
- a9097g.htm (6-K) — 38KB
- 0001654954-25-012757.txt ( ) — 39KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 10 November 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary